|

Promising Drugs for Controlling Mesothelioma Growth

ByHolly Zink
Promising Drugs for Controlling Mesothelioma Growth

A team of researchers are looking for ways to see if they could slow down the growth of mesothelioma cells. They tested two drugs called auranofin and palbociclib to stop mesothelioma from spreading in a patient’s body.

The team is from the Minneapolis VA Health Care System and the University of Minnesota.

Advancing Treatment Options for Mesothelioma

Mesothelioma is an aggressive cancer caused by asbestos exposure. Most cases of mesothelioma are pleural (about 2,000 cases a year in the U.S.) and peritoneal (less than 1,000 cases a year in the U.S.). Pleural mesothelioma is found in the lungs while peritoneal mesothelioma is found in the abdominal cavity.

The usual treatment involves a combination of chemotherapy, radiation therapy, and surgery. Immunotherapy is also a type of treatment that is being used more often.

For many patients, mesothelioma is hard to treat, and the outlook is not good. Mesothelioma is hard to diagnose and takes a long time to show symptoms. This means that it can spread to dangerous levels before a person is diagnosed and can begin treatment.

In previous studies, researchers have found that certain proteins in our cells and the process of cell division can make mesothelioma grow. They discovered that by blocking these proteins, they could stop the cancer from spreading.

Investigating Breakthrough Drugs to Halt Mesothelioma Progression

In this new study, the research team tested two drugs called auranofin and palbociclib to see if they could slow down mesothelioma cells. Auranofin is already approved by the FDA to treat rheumatoid arthritis. Palbociclib is sometimes used to treat breast cancer.

They found that these drugs, used together or separately, were able to stop the growth of the mesothelioma cells by blocking targeted proteins.

The researchers hope that more research on these two drugs can lead to a new type of treatment for mesothelioma.

Source

Kratzke M, Scaria G, Porter S, Kren B, Klein MA. Inhibition of Mitochondrial Antioxidant Defense and CDK4/6 in Mesothelioma. Molecules. 2023;28(11):4380. Published 2023 May 27. doi:10.3390/molecules28114380. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254447/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Victims’ Victory in Pennsylvania

    ByAlex Strauss

    Workers and their families have won a victory in Pennsylvania after the state Supreme Court ruled that they could sue former employers over late-manifesting industrial diseases like mesothelioma. The decision focused on a provision in Pennsylvania’s Workers’ Compensation Act that says workers cannot sue an employer if their occupational disease occurred more than 300 weeks after their on-the-job exposure. While many occupational injuries and diseases occur within weeks or months of exposure to a toxin, asbestos diseases like mesothelioma are a notable exception. Believed to be caused by chronic irritation from inhaled or ingested asbestos fibers, mesothelioma does not usually begin to cause symptoms until at least a decade after exposure. Expressing the opinion of the majority, Supreme Court Justice…